Treatment |
Route |
Glucose Levels at Varying Times (mg/dL) |
|
|
0hr |
1hr |
2hr |
3hr |
4hr |
12hr |
24hr |
Group I |
IP |
60.50±5.57 |
59.25 ± 4.99 |
60.75 ± 5.56 |
61.25 ± 4.35 |
58.50 ± 7.19 |
51.50 ± 1.29 |
53.00 ± 1.83 |
Oral |
66.50 ± 9.98 |
67.25 ± 8.62 |
69.50 ± 7.05 |
69.50 ± 5.45a |
68.75 ± 6.85a |
62.00 ± 9.83a |
61.25 ± 9.61 |
Group II |
IP |
222.25 ± 11.33A |
223.75 ± 11.15B |
227.75 ± 10.63B |
233.25 ± 11.09B |
239.00 ± 11.10C |
250.25 ± 15.48B |
261.25 ± 15.37B |
Oral |
204.25 ± 8.66a |
206.25 ± 8.46b |
208.00 ± 8.13b |
209.75 ± 8.54b |
212.00 ± 7.87 |
218.75 ± 10.21c |
227.25 ± 6.65c |
Group III |
IP |
220.25 ± 10.78A |
132.00 ± 17.57A |
64.25 ± 3.30 |
57.50 ± 2.65 |
54.25 ± 1.71 |
51.25 ± 1.89 |
51.25 ± 1.71 |
Group IV |
Oral |
193.75 ± 22.69a |
96.50 ± 10.85a |
70.25 ± 7.63 |
58.75 ± 5.91 |
51.75 ± 2.22 |
49.50 ± 1.29 |
53.50 ± 1.29 |
Extract |
|
|
|
|
|
|
|
|
Group V |
IP |
215.50 ± 12.66A |
123.50 ± 16.70A |
94.50 ± 7.42A |
83.00 ± 8.60A |
74.25 ± 5.38A |
97.75 ± 2.99A |
114.50 ± 6.35A |
Oral |
198.75 ± 18.34a |
105.50 ± 4.20a |
89.00 ± 3.16a |
81.25 ± 1.71a |
70.75 ± 1.708a |
95.00 ± 4.32b |
116.50 ± 4.20b |
Group VI |
IP |
222.00 ± 15.64A |
107.75 ± 7.04A |
88.00 ± 5.72A |
79.75 ± 3.30A |
79.25 ± 2.06B |
94.25 ± 2.50A |
113.75 ± 5.85A |
Oral |
190.75 ± 14.59a |
102.00 ± 2.58a |
79.75 ± 1.71a |
78.25 ± 1.50a |
77.00 ± 1.83a |
90.25 ± 2.22b |
102.00 ± 3.74a |
Group VII |
IP |
226.50 ± 11.96A |
108.75 ± 5.38A |
87.00 ± 3.92A |
74.00 ± 4.08A |
65.00 ± 1.41 |
83.50 ± 6.86A |
110.00 ± 4.97A |
Oral |
204.50 ± 9.98a |
104.75 ± 4.86a |
91.00 ± 6.16a |
80.75 ± 7.41a |
72.50 ± 1.83a |
89.50 ± 3.70b |
111.00 ± 3.56a |
|
Results are expressed as Means ± SEM for four animals per group. Means for intraperitoneally (IP) administered drugs followed by similar upper case letters are not significantly different at p<0.05 by ANOVA and Boniferroni-Holm test; Means for orally (oral) administered drugs followed by similar lower case letters are not significantly different at p<0.05 by ANOVA and Boniferroni-Holm test. Group I represents the normal control rats orally or intraperitoneally administered with 0.1 ml physiological saline; Group II represents diabetic rats orally or intraperitoneally administered with 0.1 ml physiological saline; Group III represents diabetic rats intraperitoneally administered with insulin at 1 IU/kg body weight; Group IV represents diabetic rats orally administered with glibenclamide at 3 mg/kg body weight; Group V represents diabetic rats orally and intraperitoneally administered with aqueous extracts of C. pareira at 50 mg/kg body weight; Group VI represents diabetic rats orally and intraperitoneally administered with aqueous extracts of C. pareira at 100 mg/kg body weight; Group VII represents diabetic rats orally and intraperitoneally administered with aqueous extracts of C. pareira at 150 mg/kg body weight. mg/kg bw stands for mg/kg body weight. |
Table 1: Effects of three therapeutic doses of aqueous leaf extracts of C. pareiraat different times on blood glucose levels in alloxan induced diabetic rats. |